Legislative, Regulatory & Legal

It's been over three years since the initial complaint in the case was launched

A four-year agreement brought an end to a months-long dispute marred by verbal and physical confrontations on the picket lines

A company whose prescription opioid marketing practices are being blamed for sparking the addiction and overdose crisis says it’s helping to fund an effort to make a lower-cost overdose antidote.

Provinces must often make ad hoc decisions about which expensive drugs for rare diseases to cover, but some researchers argue that needs to change

The ongoing NAFTA renegotiations could put a Canadian national pharmacare program in jeopardy, and could have a particular impact on Canadians who need expensive arthritis drugs

Nova Scotia's premier says a hospital's decision to turn away a young sexual assault victim was unacceptable, and Stephen McNeil is now calling on the province's Health Department to determine who was responsible.